Synergy Innovation Signs Joint Research Agreement for Domestic Production of Cell Culture Media

[Asia Economy Reporter Hyunseok Yoo] Synergy Innovation announced on the 18th that it has signed a joint research business agreement with the Bio-Synthesis Research Group of the KAIST (Korea Advanced Institute of Science and Technology) Global Frontier Project to localize cell culture media.

Cell culture media is one of the three core elements (cells, media, devices) necessary for cell culture and is used in the biopharmaceutical industry for vaccines, new drugs, antibodies, and stem cell therapies. It is a high value-added industry with high growth potential. The domestic cell culture media market is about 400 billion KRW in size and is growing annually, but most research and industrial media are currently dependent on imports.

Through this agreement, both parties plan to jointly conduct research and development of cell culture media materials and collaborate on the localization of cell culture media products, including the exchange of specialized personnel. In particular, they plan to develop various cell culture media focusing on Fetal Bovine Serum (FBS), which is widely used in research institutes and companies.

A company official stated, “Through joint research with the KAIST research group, we will take the lead in localizing cell culture media essential to the biopharmaceutical industry,” adding, “Synergy Innovation will establish a foundation to grow beyond the number one domestic media market position to become a global cell culture media company.”

Meanwhile, Synergy Innovation recently completed the development of viral detection transport media following its core business of microbial culture media and is expanding its business area to include cell culture media.

This content was produced with the assistance of AI translation services.